Literature DB >> 12504706

Bilateral optic nerve infiltration in central nervous system leukemia.

Lisa S Schocket1, Mina Massaro-Giordano, Nicholas J Volpe, Steven L Galetta.   

Abstract

PURPOSE: To report the case of a 58-year-old man with sequential bilateral retrolaminar leukemic infiltration of the optic nerves who presented with normal-appearing optic nerves and no optic nerve enhancement.
DESIGN: Interventional case report.
METHODS: A 58-year-old man with chronic myelogenous leukemia (CML) developed progressive vision loss to no light perception in both eyes over four days. The patient received 14 doses of external beam irradiation and 10 cycles of intrathecal cytarabine. Despite treatment, he developed optic nerve pallor, and visual acuity remained no light perception in both eyes.
CONCLUSIONS: In a patient with leukemia, leukemic optic nerve infiltration may occur even with normal-appearing optic nerves and a normal magnetic resonance image. It is important to maintain a high clinical suspicion for optic nerve infiltration so that prompt local irradiation may be initiated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504706     DOI: 10.1016/s0002-9394(02)01847-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  [Unilateral loss of visual function with edema of the optic nerve in a 35-year-old male patient].

Authors:  A Zimmermann; F Weinand; B Lorenz
Journal:  Ophthalmologe       Date:  2010-11       Impact factor: 1.059

2.  Acute Myeloid Leukemia Relapse Presenting as Complete Monocular Vision Loss due to Optic Nerve Involvement.

Authors:  Shyam A Patel
Journal:  Case Rep Hematol       Date:  2016-09-07

3.  A Rare Monocytic Crisis of Chronic Myelogenous Leukemia Presenting with Unusual Extramedullary Manifestations and an Atypical (14;22)(q24;q11.2) Translocation in the Bone Marrow.

Authors:  Morihiro Inoue; Masao Hagihara; Tomoyuki Uchida; Jian Hua; Takeshi Nakajima; Shogo Tajima; Yasunori Ota
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.